|Bid||45.11 x 800|
|Ask||47.65 x 1000|
|Day's Range||45.48 - 46.75|
|52 Week Range||25.01 - 55.58|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2023 - Feb 24, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.36|
Subscribe to Yahoo Finance Plus to view Fair Value for PTCT
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation Document recommending Translarna™ (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales. Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged 2 years and older who can walk.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program. Through this program, PTC awards grants to patient advocacy organizations who are committed to developing initiatives that address the needs of the Duchenne Muscular Dystrophy (Duchenne) community. Organizations may submit entries to fund 2023 projects focused on one of two categories: Innovation or Transition to Adulthood.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an aggregate of 39,585 shares of its common stock and 13,045 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 33 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation.